Preventing cardiac events and restenosis after percutaneous coronary intervention

JAMA

Volumn 287, Issue 24, 2002, Pages 3259-3261

  Sopko, George ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HEART DISEASE; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; RISK FACTOR; STENT; TREATMENT PLANNING;

EID: 0037178583     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.24.3259     Document Type: Editorial

References (44)

1. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization
2. Comparative efficacy of γ irradiation for treatment of in-stent restenosis in saphenous vein graft versus native coronary artery in-stent restenosis: An intravascular ultrasound study
3. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease
4. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial
5. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial
6. Proceedings of the National Heart, Lung, and Blood Institute Workshop on the outcome of percutaneous transluminal angioplasty
7. Low density lipoprotein level is associated with increased rate after coronary angioplasty
8. Lipoprotein(a) in restenosis after percutaneous transluminal angioplasty and coronary artery disease
9. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the National Heart, Lung, and Blood Institute
10. Follow-up clinical results in patients undergoing percutaneous transluminal coronary angioplasty
11. Influence of balloon size on initial success, acute complications, and restenosis after percutaneous transluminal coronary angioplasty: A prospective randomized study
12. Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood: Effects of different stenoses on thrombus growth
13. C-fos protein can induce cellular transformation: A novel mechanism of activation of a cellular oncogene
14. Molecular cloning of gene sequences regulated by platelet-derived growth factor
15. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury
16. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty
17. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty
18. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty
19. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: A randomized study
20. A controlled trial of cortico-steroids to prevent restenosis after coronary angioplasty
21. Lovastatin blocks basic fibroblast growth factor-induced mitogen-activated protein kinase signaling in coronary smooth muscle cells via phosphatase inhibition
22. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: A study in atherosclerotic hypercholesterolemic rabbit
23. Lack of effect of lovastatin on restenosis after coronary angioplasty
24. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells
25. Hypercholestermia is associated with enhanced angiotensin AT-1 receptor expression
26. The pathogenesis of coronary artery disease and the acute coronary syndromes
27. Hypercholesteremia increases superoxide anion production
28. Small oxidative changes in atherogenic LDL concentrations irreversibly regulate adhesiveness of human endothelial cells: Effect of the lazaroid U74500A
29. Leukocyte-endothelium interaction during the early stages of hypercholesteremia in the rabbit
30. Administration of tumor necrosis factor-alpha in vivo depress endothelium-dependent relaxation
31. Endothelial stunning following a brief exposure to link infection and infarction
32. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent vasomotion
33. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
34. Direct vascular effects of HMG-CoA reductase inhibitors
35. Effect of new HMG-CoA reductase inhibitor cerivastatin on migration, proliferation and cholesterol synthesis in arterial myocytes
36. Protein prenylation
37. CoA-reductase inhibitors: In vivo effects on carotid intimal thickening in normocholesteremic rabbit
38. Simvastatin inhibits the oxidation of low-density lipoprotein by activated human monocyte-derived macrophages
39. Simvastatin decreases aldehyde production derived from lipoprotein oxidation
40. Effects of lovastatin therapy on susceptibility of LDL to oxidation during alpha-tocopherol supplementation
41. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
42. Pharmacological control of the mevalonate pathways: Effect on arterial smooth muscle cell proliferation
43. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesteremic men